Fibromatosis: Current strategies for treatment

Current Opinion in Orthopaedics

Volumn 14, Issue 6, 2003, Pages 405-412

  Shih, Helen A ^a   Hornicek, Francis J ^a   DeLaney, Thomas F ^a   Harmon, David C ^a   Suit, Herman D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aggressive fibromatosis; Desmoid tumors

Indexed keywords

ACETIC ACID; ALCOHOL; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; GOSERELIN; IMATINIB; INTERFERON; METHOTREXATE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; RETINOIC ACID; SOMATOSTATIN DERIVATIVE; SULINDAC; TAMOXIFEN; TESTOLACTONE; TOREMIFENE; VINBLASTINE; YTTRIUM 90;

ABDOMINAL TUMOR; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DESMOID TUMOR; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; FIBROMATOSIS; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MESENTERY TUMOR; MOLECULAR DYNAMICS; MOLECULAR GENETICS; MORBIDITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SALVAGE THERAPY; TECHNIQUE; TOXICITY; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0242607067     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-200312000-00009     Document Type: Review

References (58)

1. MacFarlane J: Clinical report of surgical practice of the Glasgow Royal Infirmary. 1832:63-66.
2. Muller J: Uber den feineren Bau und die Formen der krankhaften Geschwulste. Berlin: G. Reimer; 1838:60.
3. Reitamo J, Hayry P, Nykyri E, et al.: The desmoid tumor: Incidence, sex, age and anatomical distribution in Finnish population. Amer J Clin Pathol 1982, 77:665-673.
4. Gronchi A, Casali PG, Mariani L, et al.: Quality of surgery and outcome in extraabdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clinical Oncol 2003, 21:1390-1397. This study represents the largest cohort of patients with desmoid tumors presented to date. Outcomes of 203 patients with gross total resection of their disease are reported.
5. Zlotecki R, Scarborough MT, Morris CG, et al.: External Beam Radiotherapy for Primary and Adjuvant Management of Aggressive Fibromatosis. Int J Radiat Oncol Biol Phys 2002, 54:177-181. This article reviews the outcome of 65 patients with desmoid tumors treated at the University of Florida with surgery and radiation.
6. Merchant N, Lewis JJ, Woodruff JM, et al.: Extremity and trunk desmoid tumors. Cancer 1999, 86:2045-2052.
7. Spear M, Jennings LC, Mankin HJ, et al.: Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998, 40:637-645.
8. Nuyttens J, Rust PF, Thomas CR Jr, et al.: Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative reveiw of 22 articles. Cancer 2000, 88:1517-1523.
9. Griffioen G, Bus PJ, Vasen HF, et al.: Extracolonic manifestations of familial adenomatous polyposis: desmoid tumors, and upper gastrointestinal adenomas and carcinomas. Scand J Gastroenterol Suppl 1998, 225:85-91.
10. Bertario L, Russo A, Sala P, et al.: Multiple approaches to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clinical Oncol 2003, 21:1698-1707. Using DNA and known phenotypes from 953 FAP patients, the authors seek to make correlations between the APC gene mutation site and FAP phenotype.
11. Clark S, Phillips R: Desmoids in familial adenomatous polyposis. Brit J Surg 1996, 83:1494-1504.
12. Loccufier A, Vanhulle A, Moreels R, et al.: Gardner syndrome and desmoid tumors. Acta Chirug 1993, 93:230-232.
13. Kaplan D, Levine E: Desmoid tumor arising in a laparoscopic trocar site. Amer Surg 1998, 64:388-390.
14. Lynch H, Fitzgibbons R: Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature reveiw. Am J Gastroent 1996, 91:2598-2601.
15. Sorensen A, Keller J, Nielsen OS, et al.: Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1-27 years. Acta Orthop Scand 2002, 73:213-219. Local recurrence-free survival rates in 72 patients from Denmark with desmoid tumors treated with surgery with or without radiation are reviewed.
16. Park H, Pyo HR, Shin KH, et al.: Radiation treatment for aggressive fibromatosis: findings from observed patterns of local failure. Oncology 2003, 64:346-352. A recent report of 24 patients with desmoid tumors treated primarily with radiation is reviewed.
17. Jelinek J, Stelzer KJ, Conrad E, et al.: The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001, 50:121-125.
18. Ballo M, Zagars G, Pollack A: Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998, 42:1007-1014.
19. Schulz-Ertner D, Zierhut D, Mende U, et al.: The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol 2002, 178:78-83. This article from the University of Heidelberg reviews their recent experience of treating 28 patients with desmoid tumors with surgery and radiation.
20. Goy B, Lee SP, Eilber F, et al.: The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997, 39:659-665.
21. Acker J, Bossen E, Halperin E: The management of desmoid tumors. Int J Radiat Oncol Biol Phys 1993, 26:851-858.
22. Smith A, Lewis JJ, Merchant NB, et al.: Surgical management of intraabdominal desmoid tumors. Brit J Surg 2000, 87:608-613.
23. Janinis J, Patriki M, Vini L, et al.: The pharmacological treatment of aggressive fibromatosis: a systemic review. Ann Oncol 2003, 14:181-190. The various drug approaches to treating desmoid tumors are outlined here, with results of individual studies summarized.
24. Kuhn M, Wang X, Payne WG, et al.: Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren's affected palmar fascia. J Surg Res 2002, 103:146-152.
25. Tsukada K, Church JM, Jagelman DG, et al.: Noncytotoxic drug therapy for intraabdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992, 35:29-33.
26. Poon R, Smits R, Li C, et al.: Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene 2001, 20:451-460.
27. Okuno S, Edmonson J: Combination chemotherapy for desmoid tumors. Cancer 2003, 97:1134-1135.
28. Wright M, Schuler B, Szabo E, et al.: Sustained partial response of an intra-abdominal desmoid tumor treated with gemcitabine, 5-fluorouracil and leucovorin. Ann Oncol 2003, 14:659-660.
29. Azzarelli A., Gronchi A, Bertulli R, et al.: Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001, 92:1259-1264.
30. Poritz L, Blackstein M, Berk T, et al.: Extended follow-up of patients treated with cytotoxic chemotherapy for intraabdominal desmoid tumors. Dis Colon Rectum 2001, 44:1268-1273.
31. Lynch H, Fitzgibbons R Jr, Chong S, et al.: Use of doxorubicin and dacarbazine for the management of unresectable intraabdominal desmoid tumors in Gardner's syndrome. Dis Colon Rectum 1994, 37:260-267.
32. Weiss A, Horowitz S, Lackman R: Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999, 22:193-195.
33. Skapek S, Hawk BJ, Hoffer FA, et al.: Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clinical Oncol 1998, 16:3021-3027.
34. Baliski CR, Temple WJ, Arthur K, et al.: Desmoid tumors: a novel approach for local control. J Surg Oncol 2002, 80:96-99. Results of trimodality therapy with neoadjuvant chemoradiation are reported in a small cohort of 13 patients.
35. Mace J, Sybil Biermann J, Sondak V, et al.: Response of extraabdominal desmoid tumors to therapy with imatinib meslyate. Cancer 2002, 95:2373-2379. C-kit and PDGFR expression in desmoid tumors is assayed in nine patients with standard therapy refractory desmoid tumors. Trials of imatinib in two patients are discussed.
36. Lucas D, al-Abbadi M, Tabaczka P, et al.: c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003, 119:339-345.
37. Miettinen M: Are desmoid tumors KIT positive? Am J Surg Pathol 2001, 25:549-550.
38. De Pas T, Bodei L, Pelosi G, et al.: Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. Brit J Cancer 2003, 88:645-647. A novel therapy for refractory desmoid tumors is described. Patients with somatostatin receptor analog are treated with yttrium-90-labeled somatostatin analog.
39. Clark T: Percutaneous chemical ablation of desmoid tumors. J Vasc Inter Radio 2003, 14:629-633. This article reviews two cases of successfully treated desmoid tumors with CT-guided injection of ethanol and acetic acid or acetic acid alone.
40. Mertens F, Willen H, Rydholm A, et al.: Trisomy 20 is a primary chromosome aberration in desmoid tumors. Int J Cancer 1995, 63:527-529.
41. Bridge J, Swarts SJ, Buresh C, et al.: Trisomies 8 and 20 characterize a subgroup of benign fibrous lesions arising in both soft tissue and bone. Am J Path 1999, 154:729-733.
42. Qi H, Dal Cin P, Hernandez JM, et al.: Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet 1996, 92:147-149.
43. Fletcher J, Naeem R, Xiao S, et al.: Chromosome aberrations in desmoid tumors. Cancer Genet Cytogenet 1995, 79:139-143.
44. Kouho H, Aoki T, Hashimoto H: Clinicopathological and interphase cytogenetic analysis of desmoid tumors. Histopathol 1997, 31:336-341.
45. De Wever I, Dal Cin P, Fletcher CD, et al.: Cytogenetic, clinical and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP study group. Mod Pathol 2000, 13:1080-1085.
46. Morin PJ, Sparks AB, Korinek V, et al.: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
47. Saito T, Oda Y, Tanaka K, et al.: Beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumors. J Pathol 2001, 195:222-228.
48. Saito T, Oda Y, Kawaguchi K, et al.: Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by Taqman polymerase chain reaction. Lab Invest 2002, 82:97-103.
49. Couture J, Mitri A, Lagace R, et al.: A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet 2000, 57:205-212.
50. Tejpar S, Nollet F, Li C, et al.: Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999, 18:6615-6620.
51. Alman B, Li C, Pajerski ME, et al.: Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Path 1997, 151:328-334.
52. Miyoshi Y, Iwao K, Nawa G, et al.: Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 1998, 10:591-594.
53. Cheon S, Cheah AY, Turley S, et al.: Beta-catenin stabilization dysregulates mesenchymal cell proliferation, motility and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002, 99:6973-6978. Transcriptional activity of β-catenin during proliferation or tissue healing is assessed. Phenotypic responses to inducible mutant-stabilized β-catenin protein are studied.
54. Plukker J, van Oort I, Vermey A, et al.: Aggressive fibromatosis (non-familial desmoid tumor): Therapeutic problems and the role of adjuvant radiotherapy. Brit J Surg 1995, 82:510-514.
55. Posner M, Shiu MH, Newsome JL, et al.: The desmoid tumor: not a benign disease. Arch Surg 1989, 124:191-196.
56. Markhede G, Lundgren L, Bjurstam N, et al.: Extraabdominal desmoid tumors. Acta Orthop Scand 1986, 57:1-7.
57. Catton C, O'Sullivan B, Bell R, et al.: Aggressive fibromatosis: optimisation of local management with a retrospective failure analysis. Radiother Oncol 1995, 34:17-22.
58. Belchetz L, Berk T, Bapat BV, et al.: Changing causes of mortality in patients with FAP. Dis Colon Rectum 1996, 39:384-387.